Acotec Scientific Holdings (HKSE:06669) Cash And Cash Equivalents : HK$697.4 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Acotec Scientific Holdings Cash And Cash Equivalents?

Acotec Scientific Holdings's quarterly cash and cash equivalents declined from Dec. 2022 (HK$1,101.59 Mil) to Jun. 2023 (HK$1,036.66 Mil) but then stayed the same from Jun. 2023 (HK$1,036.66 Mil) to Dec. 2023 (HK$697.42 Mil).

Acotec Scientific Holdings's annual cash and cash equivalents declined from Dec. 2021 (HK$1,392.45 Mil) to Dec. 2022 (HK$1,101.59 Mil) and declined from Dec. 2022 (HK$1,101.59 Mil) to Dec. 2023 (HK$697.42 Mil).

Acotec Scientific Holdings Cash And Cash Equivalents Historical Data

The historical data trend for Acotec Scientific Holdings's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acotec Scientific Holdings Cash And Cash Equivalents Chart

Acotec Scientific Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

35.08

174.37

1,392.45

1,101.59

697.42

Acotec Scientific Holdings Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial				1,392.45	1,245.60	1,101.59	1,036.66	697.42

Acotec Scientific Holdings Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Acotec Scientific Holdings (HKSE:06669) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Acotec Scientific Holdings Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Acotec Scientific Holdings's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Acotec Scientific Holdings (HKSE:06669) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acotec Scientific Holdings Ltd (HKSE:06669) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

7W3:Germany

Address

16 North Hongda Road, 4-5th Floor, Building No. 1, Beijing Economic-Technological Development Area, Beijing, CHN

Website

http://www.acotec.cn

Acotec Scientific Holdings Ltd is a medical device company. The company is focused on providing leave nothing behind treatment solutions for vascular diseases. It has developed a suite of interventional medical devices featuring world- leading technologies, notably in the fields of drug-coated balloons and thrombus aspiration catheters. The company's commercialized product is Semi-compliant PTCA Balloon (YAN) is a product designed for dilation in coronary artery or coronary artery bypass vessels stenosis to improve myocardial perfusion. Geographically, the company operates from Mainland China, Europe and Other countries and regions. Majority of revenue is generated from Mainland China.

Executives

Vistra Trust (singapore) Pte. Limited	2301 Trustee
Nexus Partners Group Limited	2201 Interest of corporation controlled by you
Cosmic Elite Holdings Limited	2101 Beneficial owner
Li Jing	2201 Interest of corporation controlled by you
Cpechina Fund Iii, L.p.	2201 Interest of corporation controlled by you
Cpe Funds Iii Limited	2201 Interest of corporation controlled by you
Ca Medtech Investment Iii Limited	2201 Interest of corporation controlled by you
Ca Medtech Investment Ii Limited	2201 Interest of corporation controlled by you
Ca Medtech Investment (cayman) Limited	2101 Beneficial owner
Cpe Holdings Limited	2201 Interest of corporation controlled by you
Cpe Holdings International Limited	2201 Interest of corporation controlled by you
Cpe Gof Gp Limited	2201 Interest of corporation controlled by you
Cpe Global Opportunities Fund, L.p.	2201 Interest of corporation controlled by you
Boston Scientific Corporation	2201 Interest of corporation controlled by you
Cpechina Fund Iii, L. P.

Acotec Scientific Holdings (HKSE:06669) Headlines

No Headlines